Skip to main content
main-content

08-12-2019 | Haematology | Video

ASH 2019 | Short delay from diagnosis to treatment may not be a bad thing in AML

Christoph Röllig reports findings suggesting that waiting for genetic and laboratory test results in order to get the right treatment may be a reasonable approach for clinically stable patients with acute myeloid leukaemia (7:47).

Funding for independent interviews at ASH 2019 was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland.

See the research in context now

with trial summaries, expert opinion and congress coverage

Image Credits